Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences Center Accelerator Loan

Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences 
Center Accelerator Loan 
WELLESLEY, MA -- (Marketwired) -- 10/07/13 --  Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company
and developer of AC5(TM), a novel product aimed at controlling
bleeding and fluid loss in order to provide faster and safer surgical
and interventional care, is pleased to announce that the
Massachusetts Life Sciences Center (the "Center"), a quasi-public
agency tasked with implementing the state's $1 billion Life Sciences
Initiative, has concluded the requisite steps to award Arch with a $1
million dollar Accelerator Loan. 
The Accelerator Loan Program, the Center's flagship investment
program, supports companies by providing loans of up to $1 million
that will match grants and investments from the federal government,
foundations, non-profit agencies, institutional investors, and other
sources of capital. By leveraging other sources of capital, the
Accelerator Loan Program will provide support that enables companies
to conduct vital research and development and attract subsequent
investment, improving the odds of bringing cutting-edge innovation to
the marketplace. To date, the Center has funded 24 companies through
this program. 
Terrence W. Norchi, M.D., CEO of Arch Therapeutics, stated, "The
Massachusetts Life Sciences Center, representing the Commonwealth of
Massachusetts, has been incredibly supportive and we are very pleased
to be a member of the short list of awardees. The exceptionally
rigorous diligence and review process was undertaken with the
participation of highly regarded members from the Massachusetts
investment community as well as household names in the area's life
sciences academic and industrial circles. The loan, itself, is
significant to Arch because it provides a clear level of validation
for our plans to develop a novel technology into new products
targeting markets of unmet clinical need and it further speaks to the
quality of our team. We intend to use the funding effectively and
responsibly as we continue to grow our business."  
Applicants were subjected to a double-blind, rigorous peer review and
subsequent evaluation by the Center's Scientific Advisory Board
(SAB). Applicants were then further screened by the Center's
Investment Sub-Committee of the Board of Directors, through a process
that included a live presentation by finalists. Final awards were
determined by the Center's Board of Directors. Arch was one of four
companies authorized in December 2012 by the Center' Board in the
sixth round of the program to receive a loan. The Company received
the maximum loan amount through the program. 
"The Center's Accelerator Loan Program fills a critical gap in the
life cycle of promising early-stage companies with a high potential
for technology commercialization, rapid growth and private equity
financing," said MLSC President & CEO, Susan Windham-Bannister, Ph.D.
"This investment in Arch Therapeutics reflects our commitment to
early-stage companies working to produce therapies that will improve
the human condition and address unmet medical needs, in this case
regarding advanced peptide technologies." 
Arch Therapeutics, Inc. is a medical device company developing a
novel approach to stop bleeding (hemostasis) and control leaking
(sealant) during surgery and trauma care. Arch is developing products
based on an innovative self-assembling peptide technology platform to
make surgery and interventional care faster and safer for patients.
Arch's flagship development stage product candidate, known as
AC5(TM), is being designed to achieve hemostasis in minimally
invasive and open surgical procedures. 
In related news, the company wishes to advise that in response to a
growing need for additional office space, it has relocated to a new
headquarters in the vicinity. Accordingly all future correspondence
should be directed to: 
Arch Therapeutics, Inc.
 20 William Street, Suite 270
 Wellesley, MA
02481 
Additional details of the Company's business, finances, appointments
and agreements can be found as part of the Company's continuous
public disclosure as a reporting issuer with the Securities and
Exchange Commission ("SEC") available at www.sec.gov. For more
information, visit our website at www.archtherapeutics.com.  
About the Massachusetts Life Sciences Center
 The Massachusetts Life
Sciences Center (MLSC) is an investment agency that supports life
sciences innovation, research, development and commercialization. The
MLSC is charged with implementing a 10-year, $1-billion, state-funded
investment initiative. These investments create jobs and support
advances that improve health and well-being. The MLSC offers the
nation's most comprehensive set of incentives and collaborative
programs targeted to the life sciences ecosystem. These programs
propel the growth that has made Massachusetts the global leader in
life sciences. The MLSC creates new models for collaboration and
partners with organizations, both public and private, around the
world to promote innovation in the life sciences. For more
information, visit www.masslifesciences.com. 
About the Accelerator Loan Program 
 In order to expand
life-sciences-related employment opportunities, promote
health-related innovations and stimulate research and development,
manufacturing and commercialization in the life sciences, the
Accelerator Loan Program provides loans to companies engaged in life
sciences research and development, commercialization, and
manufacturing in Massachusetts. Target entities are generally
early-stage life sciences companies with a high-potential for
technology commercialization, rapid growth and downstream private
equity financing. The program is designed to help sustain these
companies through a critical stage of development and to leverage
additional sources of capital to bring cutting-edge innovation to the
marketplace. 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
is a medical device company developing a novel approach to stop
bleeding (hemostasis) and control leaking (sealant) during surgery
and trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5(TM), is being
designed to achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at www.archtherapeutics.com.  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at
www.sec.gov. 
On Behalf of the Board,
 Terrence W. Norchi, MD.
 Arch Therapeutics,
Inc. 
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com 
Website: www.archtherapeutics.com 
 
 
Press spacebar to pause and continue. Press esc to stop.